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Abstract: 
Elevated low density lipoprotein cholesterol (LDL-C) levels are associated 
with an increased risk for cardiovascular disease (CVD). Statins have been 
the cornerstone of lipid therapy to lower LDL-C for the last two decades, 
but despite significant clinical efficacy in a majority of patients, a large 
residual risk remains for the development of initial or recurrent 
atherosclerotic cardiovascular disease. In addition, owing to side effects, a 
significant percentage of patients cannot tolerate any statin dose or a high 
enough statin dose.  Thus, novel therapeutic agents are currently being 
developed to lower LDL-C levels further. This review will highlight these 
novel therapeutic agents including anti-sense oligonucleotides focused on 
apolipoprotein B, proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors and microsomal triglyceride transfer protein inhibitors. For each 
therapeutic class, an overview of mechanism of action, pharmacokinetic 
data, and efficacy/safety evidence will be discussed. 
 
 
 
 
 
Introduction: 
Cardiovascular disease is the leading cause of death worldwide. There is 
compelling evidence from population-based studies and clinical trials that 
low density lipoprotein cholesterol (LDL-C) reduction is an effective strategy 
to reduce coronary heart disease (CHD) events andslow CHD (1).  
Statins are powerful LDL-C lowering agents that represent the therapy of 
choice for primary and secondary prevention of cardiovascular events (2, 
3). Yet a significant proportion of patients remain at high risk. Some 
patients require larger reductions of LDL-C due to high baseline levels, 
such as those with familial hypercholesterolemia. Others develop adverse 
events and stop or discontinue current therapies (4-6). These issues 
demonstrate the need for additive or replacement therapy to statins, which 
work by inhibiting the first enzymatic reaction of endogenous cholesterol 
synthesis. This review will focus on new agents targeting other molecular 
pathways that can lower LDL-C. 
 
Transport and fate of body cholesterol 
Cholesterol originating from either de novo synthesis or from the diet is 
transported in blood by apolipoprotein (apo) B and apo A containing 
lipoproteins (Fig. 1). Apo A are associated with high density lipoproteins 
(HDL). Lipid poor HDL are produced by the liver, the intestine or derived 
from chylomicrons. They take up free cholesterol from peripheral organs 
and macrophages and deliver it to the liver where it is excreted into the bile, 
an anti-atherogenic pathway known as the reverse cholesterol transport 
(7). Apo B and apo A1-containing lipoprotein pathways are interconnected 
by a set of enzyme activities that enable lipid exchange between particles. 
Cholesterol from nascent HDL is trans-esterified with phospholipid acyl 
chains by the enzyme lecithin:cholesterol acyltransferase (LCAT) into 
cholesteryl esters. Cholesteryl esters can be transferred to apo B 
containing lipoproteins such as very low-density lipoproteins (VLDL) or 
intermediary low density lipoproteins (IDL) in exchange for triglycerides 
(TGs) by the cholesteryl ester transfer protein (CETP) (8). Plasma 
phospholipid transfer protein (PLTP) is also associated with HDL and 
transfers phospholipids between lipoproteins, modulating their size and 
composition (8). 
 
This review will focus on apoB-containing lipoproteins, represented by TG 
rich intestinal chylomicrons, and hepatic VLDL or VLDL-derived IDL and 
LDL (Fig. 1). Chylomicrons and VLDL bring fuel to peripheral organs as 
fatty acids and are progressively depleted of TGs by the action of lipases 
(9). Thus, chylomicrons are converted into remnants and VLDL into IDL 
and LDL, enriched in cholesterol. LDL is removed too slowly from the 
circulation which allows it to exert proatherogenic properties; in particular it 
can be oxidized. Oxidized LDL is a source of cholesterol accumulation and 
foam cell formation in the artery wall. 
 
Anti-sense oligonucleotides directed at apolipoprotein B 
Disease states are often characterized by an abnormal protein or enzyme. 
There are many etiologies for hypercholesterolemia, one of which is an 
increase in the activity of the 3-hydroxy-3-methylglutaryl coenzyme A 
reductase enzyme causing increased cholesterol biosynthesis (2). As their 
name implies, the 3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors (statins), inhibit the rate limiting 
enzyme for cholesterol biosynthesis. However, drugs created through 
antisense technology act differently from traditional enzyme or protein-
targeting drugs. In antisense technology, the target gene is transcribed 
normally from DNA to mRNA, but the mRNA is then intercepted by an 
antisense oligonucleotide with which it undergoes a Watson-Crick type 
hybridization reaction so that the mRNA can no longer be translated into a 
protein (10). The antisense complex becomes a target for RNase H, an 
enzyme that cleaves and destroys the mRNA-antisense oligonucleotide 
hybrid. 
 
Mipomersen is a polynucleotide of 20 bases that is complementary in 
sequence to a segment of human Apo B-100 mRNA. It specifically binds to 
Apo B-100 mRNA, blocking the translation of the gene product (10-12). The 
inhibition of production of apo-B100 in the liver decreases levels of all apo 
B-containing lipoproteins, including very low-density lipoprotein (VLDL), 
LDL, and lipoprotein (a). Mipomersen is catabolized by endonucleases and 
exonucleases, which are ubiquitously expressed in all cells and tissues, 
and is excreted in the urine (13,14). It has no dependency on cytochrome 
P450 metabolism; consequently, there is little potential for  interaction with 
statins, ezetimibe, bile acid binding resins, or other lipid lowering 
medications with which it might be used in combination. 
 
Four phase 3 trials of mipomersen have been completed in the following 
patient populations: [1] homozygous FH, which occurs in 1 of 1,000,000 
people (15); [2] heterozygous FH in patients with coronary artery disease 
(CAD) (16); [3] severe hypercholesterolemia [as defined later in this 
section] (17); and [4] hypercholesterolemia in patients at high risk for CAD 
[as defined later in this section] (18). 
 
These phase 3 trials were randomized, double blind, placebo-controlled, 
multicenter studies and in each the patients were already on stable doses 
of their maximally tolerated lipid-lowering therapies (15-18). Patients were 
administered weekly subcutaneous injections of placebo or 200 mg 
mipomersen for 26 weeks and were given the option to self-administer the 
drug.  The primary efficacy end point was the percent change in LDL-C 
from baseline to week 28 (2 weeks after the last dose), and secondary end 
points included percent changes in apo B, total cholesterol, non-HDL-C, 
TG, lipoprotein (a) [Lp(a)], VLDL, Apo A1, HDL-C, and the LDL-C/HDL-C 
ratio.  
 
Patients with homozygous FH and those with severe 
hypercholesterolemia 
achieved an average LDL-C reduction (above that achieved by 
maximum tolerated lipid-lowering therapies) of >100 mg/dL, 
representing 25% and 36% LDL-C reductions, respectively. Patients 
with heterozygous FH and CAD and those with hypercholesterolemia 
and high risk of CAD achieved an average LDL-C reduction of 28% 
and 37% from baseline LDL-C respectively. Typically, the maximal 
steady-state LDL-C reduction was achieved at 12-16 weeks. 
 
The most common adverse events leading to discontinuation with 
mipomersen treatment were mild-to-moderate injection site reactions and 
flu-like symptoms. Mipomersen has typically been shown to modestly 
increase hepatic fat (i.e., steatosis) in the range of 6%-12% (16,18,19).  
However, this effect was reversible after cessation of therapy and long-term 
extension studies have shown that in some patient’s hepatic fat decreases 
over time with mipomersen use (20). Bilirubin indices, serum albumin and 
prothrombin times were not altered by mipomersen treatment, though 8% 
had an alanine aminotransferase level greater than three times the upper 
limit of normal on two consecutive occasions.  
 
Mipomersen administration in conjunction with maximally tolerated statin 
therapy has shown great promise in phase III trials. The average LDL-C 
reduction exceeded 100mg/dl in patients with homozygous FH and severe 
hypercholesterolemia. An ongoing phase III clinical trial in Germany is 
evaluating the use of mipomersen in conjunction with LDL apheresis to 
determine whether mipomersen will result in reduced apheresis time or 
frequency. 
 
 
 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors  
The hepatic LDL receptor (LDLR) plays a central role in cholesterol 
homeostasis (21, 22). It is a large, complex protein with a binding domain 
for apo B.  After apo B (as part of an apo B–containing lipoprotein) binds to 
LDLR, the receptor–apo B complex is internalized in a clarithrin-coated pit 
and enters the hepatocyte (23). Clarithrin then dissociates from LDLR, and 
the apo B particle undergoes lysosomal degradation, releasing cholesterol. 
The LDLR is recycled back to the surface of the hepatocyte, where it can 
again bind with apo B particles, enabling efficient clearance of LDL from the 
circulation. (Fig. 2) 
 
PCSK9, a member of the proteinase K subfamily of subtilases, is a 
protease involved in regulating the level of circulating LDL-C through 
effects on LDLR. PCSK9 regulates the surface expression of LDLR by 
targeting them for lysosomal degradation.  PCSK9 accelerates the 
degradation of hepatic LDLR (24).   Thus, sustained elevation of PCSK9 
levels through gain of function variants would be associated with reductions 
in LDLR and increases in LDL-C. Conversely, inactivation of PCSK9 or 
reduction in PCSK9 levels would theoretically lead to reductions in LDL-C 
levels. 
 
In the Atherosclerosis Risk in Communities Study (25), African Americans 
who had a loss-of-function PCSK9 mutation leading to 40-mg/dL lower 
LDL-C had a 90% reduction in coronary events in their middle years, from 
ages 40 to 55. White subjects who had another loss-of-function PCSK9 
mutation, leading to 20-mg/dL lower LDL-C, had a 50% reduction in 
coronary events at the same ages. 
 
Statins, bile acid sequestrants, and ezetimibe stimulate LDLR up regulation 
by decreasing the amount of cholesterol in the hepatocyte. This is a tightly 
regulated system. However, in a counter-regulatory action by the liver, 
statins also produce PCSK9 up-regulation (26). Thus, the potential 
reduction in LDL-C provided by some LDL-C–lowering drugs is limited by 
this compensatory increase in PCSK9. 
 
The strategy of PCSK9 inhibition that has progressed farthest in clinical 
development is neutralization of PCSK9 with a selective monoclonal 
antibody. By neutralizing circulating PCSK9, monoclonal antibodies prevent 
PCSK9- mediated catabolism of LDLR, increase LDLR density on the 
surface of hepatocytes, and facilitate clearance of LDL and other 
atherogenic lipoproteins from the circulation (27). 
 
Several monoclonal antibodies to PCSK9 are in clinical trial development. 
At the time of this publication, most of the published data has come from 
studies of REGN727/SAR236553 (REGN727, Alirocumab; Regeneron 
Pharmaceuticals, Inc. [Tarrytown, NY] and Sanofi-Aventis [Reston, VA]) 
and data from phase 3 trials of AMG 145, Evolocumab (Amgen, 
Washington, DC). 
 
In the first phase 1 study of a PCSK9 monoclonal antibodies in humans, a 
group of healthy volunteers were administered either single-dose 
intravenous or subcutaneous REGN727 injections. In another phase 1 
study, a group of patients with heterozygous familial hypercholesterolemia 
or non-familial hypercholesterolemia, who were following a modified diet, 
were administered multiple subcutaneous REGN727 injections on days 1, 
29, and 43 (28). In these studies the administration of REGN727 led to 
profound effects on LDL-C concentration. Notably, a single dose in healthy 
volunteers led to 50%-70% reductions in LDL-C (Fig 3). 
 
In a 12-week placebo-controlled study in which REGN727 was injected 
every 2 weeks (Q2W) or Q4W in patients with primary 
hypercholesterolemia (29),  there was a 31% LDL-C reduction 2 weeks 
after the initial 50-mg dose that decreased further to a 40% change from 
baseline at 12 weeks (Fig 4). LDL-C levels after 12 weeks of 100- and 150-
mg Q2W doses and 200- and 300-mg Q4W doses decreased by 64%, 
72%, 43%, and 48%, respectively. These were the mean responses over 
time; however, the observed pattern was that upon injection of the PCSK9 
monoclonal antibody there was a large decrease in LDL-C levels followed 
by a gradual rebound as the monoclonal antibodies were cleared from the 
circulation. In addition to reductions in LDL-C, TG decreased slightly (- 
8.4% with 300 mg), HDL-C increased (8.5% with 300 mg), and apo A1 
levels increased at the greatest dose (4.2% with 300 mg). The incidence of 
adverse events was 45% in the group receiving placebo, 60% in the 50-mg 
Q2W, 65% in the 100-mg Q2W, 61% in the 150-mg Q2W, 67% in the 200-
mg Q4W, and 47% in the 300-mg Q4W dosing groups (29). There were no 
instances of elevated liver enzymes greater than 3 times the upper limit of 
normal (>3x ULN) or creatine kinase (>10x ULN) associated with 
administration of the PCSK9 antibody. Less than 1% of subjects reported 
muscle pain or weakness. Injection-site reactions occurred in the PCSK9 
antibody groups but were generally mild and non-progressive. 
A placebo-controlled statin combination study investigated the effects of 
150 mg of REGN727 Q2W for 8 weeks plus 80 mg/d atorvastatin or a 
maintenance dose of 10 mg/d atorvastatin (Fig. 5). In the group receiving 
atorvastatin 80 mg/d plus placebo, there was a decrease in LDL-C of 17% 
compared with a 73% reduction in the group receiving atorvastatin 80 mg/d 
plus REGN727. With the REGN727 plus atorvastatin 10 mg/d combination, 
LDL-C was decreased by 66%.  
REGN727 also significantly lowered apo B, non–HDL-C, Lp (a) and TG. 
Safety and tolerability results for the combination of atorvastatin plus 
REGN727 were also favorable (30).Three patients had elevated liver 
enzymes and none had significantly increased creatine kinase.  One of the 
patients enrolled in the study developed leukocytoclastic vasculitis that 
resolved after treatment with prednisone. Injection site skin reactions were 
also rare and mild. 
 
The Durable Effect of PCSK9 Antibody Compared with Placebo Study 
(DESCARTES) found that evolocumab administered monthly, either 
alone or in combination with a statin with or without ezetimibe (EZE), 
for 52 weeks lowered LDL-C by 57 percent in subjects with a range of 
cardiovascular risk (31). Based on screening LDL-C and NCEP-ATPIII 
risk, 901 subjects were randomized to one of four background lipid-
lowering therapies (diet alone, atorvastatin 10 mg/d, atorvastatin 80 
mg/d, atorvastatin 80 mg/d with EZE 10 mg/d). Subjects with LDL-C ≥ 
75 mg/dL following lipid therapy lead-in (median baseline range 94–
113 mg/dL) were randomized 2:1 to subcutaneous monthly 
evolocumab 420 mg or placebo. Results showed evolocumab reduced 
least squares mean (95 percent CI) LDL-C by 57 percent compared 
with placebo (P < 0.001) but responses varied, from 49 percent to 62 
percent, among background therapies. LDL-C reduction at week 12 
and week 52 were comparable (Fig 6). 
 
Another phase 3 trial, MENDEL-2, evaluated evolocumab as a 
monotherapy in 614 randomized patients with heterozygous familial 
hypercholesterolemia (HeFH) not taking statins (32). Evolocumab 
biweekly (140 mg) or monthly (420 mg) rapidly and markedly lowered 
LDL-C over 12 weeks compared with placebo or ezetimibe, reducing 
LDL-C from baseline, on average, by 55 to 57 percent more than 
placebo and 38 to 40 percent greater than ezetimibe (P < 0.001 for all 
comparisons). 
 
A third clinical trial, RUTHERFORD-2 investigated the effect of PCSK9 
inhibition with evolocumab on LDL-C levels in HeFH patients . The 12-
week, multi-center trial randomized 331 patients 2:2:1:1 to 
evolocumab 140 mg subcutaneous biweekly: evolocumab 420 mg 
subcutaneous monthly: placebo subcutaneous biweekly: placebo 
subcutaneous monthly (33). Results showed that evolocumab 
administered either biweekly or monthly yielded significant 
reductions in LDL-C in HeFH patients on statins with or without 
ezetimibe. The mean reduction of LDL-C at week 12 was 61 percent in 
the 140 mg biweekly and 56 percent in the 420 mg monthly 
evolocumab dose groups, respectively. The mean reduction of LDL-C 
at the mean of weeks 10 and 12 was 61 percent in the 140 mg 
biweekly and 63 percent in the 420 mg monthly evolocumab dose 
groups, respectively. Thus, evolocumab 140 mg biweekly and 420 mg 
monthly dosing regimens were clinically equivalent. 
 Interestingly, a recent pooled analysis of data from 1,359 patients in 
four phase II trials assessed the effects of AMG145 (evolocumab) on 
Lp(a) levels (34), the relationships between Lp(a) and lowering of LDL-
C and apo B, and finally the influence of background statin therapy. 
AMG145 treatment for 12 weeks resulted in significant mean dose-
related reductions in Lp(a) of 29.5 % and 24.5 % with 140 mg and 420 
mg every two and four weeks, respectively. Lipoprotein (a) reductions 
were significantly correlated with percentage reductions in LDL-C and 
apo B. Moreover, a trend toward a major reduction was observed in 
patients treated in combination with statins. 
 
Finally, the TESLA study (Trial Evaluating PCSK9 Antibody in 
Subjects With LDL Receptor Abnormalities) was designed to evaluate 
the safety, tolerability and efficacy of AMG 145 in a particular setting 
of subjects with homozygous familial hypercholesterolemia (HoFH) in 
which it was unknown if PCSK9 inhibition would work (35). Eight 
HoFH patients with null or defective mutations in the LDL-receptor 
were recruited and treated with AMG145 (420 mg every four weeks for 
≥12 weeks, followed by every two weeks for an additional 12 weeks) . 
After 12 weeks treatment, a 16.5 % LDL-C mean reduction from 
baseline was observed in the treated patients. However the patients 
who experienced  significant reduction of LDL-C (up to 43.6 % from 
baseline) were carriers of defective mutations in the LDLR gene, while 
no significant changes from baseline were observed in HoFH patients 
carriers of null mutations (receptor negative patients). 
 
A quarter century after approval of the first statin in 1987, reduction of LDL-
C remains the best-validated goal of treatment in atherosclerosis. PCSK9 is 
poised to be a promising molecular target to reduce levels of LDL-C and 
other atherogenic lipoproteins below levels achievable with statins. The 
monoclonal antibody approach is expected to meet an important clinical 
need for LDL-C lowering in patients with statin intolerance, those who 
cannot achieve an adequate LDL-C level with existing therapy, refractory 
hypercholesterolemia, and those who may otherwise require LDL 
apheresis. It remains to be seen whether PCSK9 inhibition will assume a 
therapeutic role in atherosclerosis and this will depend upon the results of 
large cardiovascular outcomes trials. 
 
Microsomal transfer protein inhibitors 
The microsomal triglyceride transfer protein (MTP) is involved in the 
assembly and secretion of apo B-containing lipoproteins in the liver and 
intestine (36). Mutations in the gene encoding for MTP are the molecular 
basis of abetalipoproteinemia, a rare autosomal recessive disorder 
characterized by the absence of circulating apo B-containing lipoproteins of 
both hepatic and intestinal origins (37).  The most prominent symptoms of 
abetalipoproteinemia are due to impaired absorption of dietary fat and 
predisposition to deficiency of fat-soluble vitamins, with progressive retinal 
and spinocerebellar degeneration caused by vitamin E deficiency. 
Following the discovery of the molecular cause of abetalipoprotein in the 
early 1990s (38, 39), MTP became a potential therapeutic target for the 
treatment of both hypercholesterolemia, as well as chylomicronemia. 
 
MTP is responsible for transferring neutral lipids (mainly triglycerides) and 
phospholipids onto the assembling chylomicron and VLDL particles in the 
intestine and the liver, respectively (40, 41). In the absence of functional 
MTP, as seen in the condition of abetalipoproteinemia, apo B is not 
adequately lipidated in the endoplasmic reticulum and is targeted for 
proteosomal degradation (42). As a result, chylomicrons and VLDL are not 
effectively assembled or secreted into the circulation, accounting for the 
absent apo B-containing lipoproteins in plasma. The discovery of the 
molecular basis of abetalipoproteinemia led directly to the concept that 
pharmacologic inhibition of MTP could be a strategy to reduce 
chylomicrons and LDL-C. 
 
The only systemic MTP inhibitor that has continued to be developed 
beyond phase 2 clinical trials is lomitapide (formally BMS-201038 and 
AEGR-733). In a phase 2 double-blind placebo-controlled trial in 
moderately hypercholesterolemic subjects, lomitapide was dose-titrated 
and administered alone or in combination with ezetimibe (43).  Lomitapide 
alone significantly reduced LDL-C and apo B (30 and 24%, respectively at 
10 mg/day); combined therapy with ezetimibe was associated with a larger 
LDL-C decrease (46% at 10 mg/day of both lomitapide and ezetimibe). 
However, variable gastrointestinal side effects, transaminase elevations 
and hepatic fat increases were noted in this study. 
 
Lomitapide was developed, in part, to treat homozygous familial 
hypercholesterolemia (hoFH), an autosomal dominant disorder due to 
impaired function of the LDLR. HoFH is characterized by markedly elevated 
LDL-C, often greater than 500 mg/dl, tendon xanthomas and markedly 
premature and progressive atherosclerosis. Because of the impaired 
functionality of the LDLR, hoFH patients respond inadequately to 
conventional drug therapies that work through LDLR upregulation (44-47). 
A proof-of-concept study in six hoFH patients treated with lomitapide given 
as monotherapy in a dose-escalation regimen showed that doses of 0.3 
and 1 mg/kg daily resulted in significant decreases in LDL-C, apo B and 
triglycerides, which at the higher dose were decreased by 51, 56, and 65%, 
respectively (48). The reduction in LDL-C levels was accompanied by a 
decrease in LDL-apo B production confirming that the mechanism by which 
MTP inhibition decreases LDL-C levels is by reducing the hepatic secretion 
of apoB-containing lipoproteins. 
 
The magnitude of LDL-C reduction with lomitapide in hoFH was confirmed 
in a recently published multicenter phase III study in hoFH patients, in 
which lomitapide was dose-titrated up to a maximum of 60 mg/day on top 
of standard of care, including LDL apheresis (49). During the first 26 weeks 
(efficacy phase), lomitapide was gradually escalated and concomitant 
therapy remained unchanged. The median dose of lomitapide at the end of 
the efficacy phase was 40 mg/day. LDL-C, apo B and triglycerides were 
decreased by 50, 49 and 45%, respectively (Fig 7), at week 26 as 
compared to baseline, and remained significantly reduced by 38, 43 and 
31% at the end of the study, despite the changes in concomitant treatment 
that were allowed after week 26 (49). This trial confirmed that the efficacy 
of lomitapide is additive to that of other lipid-lowering treatments, including 
LDL apheresis, and is stable over time. The combined efficacy on LDL-C 
reduction in the phase III study allowed six patients undergoing apheresis 
to either stop or decrease the frequency of apheresis treatments. 
In addition to a reduction in other apo B-containing lipoprotein parameters, 
lomitapide treatment was associated with a 15% reduction in Lp(a). The 
mechanism of this effect is not known, but it is interesting to note that 
mipomersen, which also reduces LDL-C levels via a decrease in 
production, decreases Lp(a) as well (15). 
 
As expected, based on its mechanism, MTP inhibition with lomitapide is 
associated with the presence of gastrointestinal adverse events, including 
nausea, flatulence and diarrhea. Gastrointestinal adverse events were the 
most common reason for failure to tolerate a higher dose of lomitapide, 
causing three subjects to discontinue the study. Interestingly, these 
symptoms can be partially or completely controlled with a gradual dose-
escalation regimen, as well as adherence to a low-fat diet and dosing at 
times other than at meals (48, 49). 
 
Based on its mechanism, MTP inhibition is also associated with an 
increase in liver fat content, which has historically been the major issue 
with this class of drugs. In the phase 2 study of lomitapide in hoFH patients, 
hepatic fat was measured by nuclear magnetic resonance spectroscopy at 
baseline and at the end of every 4-week dose escalation: in two of the six 
enrolled subjects, hepatic fat at the end of treatment was minimally 
increased (< 10%); in two others, hepatic fat was increased to 18–24%; 
and in the last two subjects, hepatic fat was increased more than 30% (48).  
Importantly, liver fat content and transaminase elevations were reversible 
with suspension of the drug (48).   
 
During the phase 3 study in hoFH patients treated with lomitapide, liver fat 
content increased from1% at baseline to 8.6% at the end of the efficacy 
phase (week 26) during which the dose was titrated up to a maximum of 60 
mg/day. Hepatic fat content then stabilized at this level for the rest of the 
study (8.3% at week 78). The changes in hepatic fat content were 
negatively correlated with the change in LDL-C levels (49).  Approximately 
one-third of the patients experienced an increase in alanine 
aminotranferase more than three times the upper limit of normal, and this 
was more common in subjects with greater increases in hepatic fat. 
Transaminase elevations were, however, generally transient and 
manageable with temporary dose reduction (49). 
 
Lomitapide was approved in December 2012 for the treatment of hoFH. 
The 50 % reductions in LDL-C were considered to provide benefit that 
outweighed the increase in hepatic fat. Because of the risk of liver toxicity, 
lomitapide is available only through a restricted program called the 
JUXTAPID Risk Evaluation and Mitigation Strategy Program, which will 
require certification of all health care providers who prescribe it and 
pharmacies that dispense it. Combination with cytochrome P450 3A4 
(CYP3A4) inhibitors increases exposure to lomitapide. Thus, lomitapide 
should not be used with strong and moderate CYP3A4 inhibitors, and 
dosage limitation (not exceeding 30 mg/d) is also required when 
administering concomitantly with weak CYP3A4 inhibitors. 
 
 
 
CONCLUSIONS: 
It has been close to  3 decades (IS THIS CORRECT???) since lovastatin 
(Mevacor) was approved to lower LDL-C. Since that time, statins have 
been shown to significantly reduce all forms of atherosclerotic disease, 
especially CHD and stroke. But despite significant clinical efficacy in a 
majority of patients, a large residual risk remains for the development 
of initial or recurrent atherosclerotic cardiovascular disease. In 
addition, owing to side effects, a significant percentage of patients 
cannot tolerate any statin dose or a high enough statin dose. Clinical 
practice guidelines from the American Heart Association and 
American College of Cardiology (2) recommend at least a moderate to 
high intensity statin therapy for secondary prevention. There remains 
a large number of patients who are statin averse for whom there are 
limited alternatives for achieving significant LDL-C reductions (5). 
Thus, these newer classes of LDL-C lowering agents may hopefully fill an 
important clinical need for patients with statin intolerance, patients with high 
residual risk despite statin therapy, provide additive therapy in addition to 
statin therapy for patients with refractory hypercholesterolemia, and those 
who may otherwise require LDL apheresis. 
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FIGURE LEGENDS 
1. Figure 1: Overview of lipoprotein metabolism in humans.  
 
2. Figure 2: Mechanism of PCSK9 inhibition with monoclonal antibodies. 
Reprinted with permission from Lambert et al. 
 
 
 
3. Figure 3: Percent changes in LDL-C after increasing single doses of 
monoclonal antibody for PCSK9 (SAR236553/REGN 727) among 
healthy volunteers. Reprinted with permission from Stein et al. 
 
 
 
4. Figure 4: Percent changes from baseline in LDL-C after 50-, 100-, 
150-, 200-, and 300-mg doses of PCSK9 monoclonal antibody 
(SAR236553/REGN727) every 2 weeks for 12 weeks in patients with 
primary hypercholesterolemia. Reprinted with permission from 
McKenney et al. 
 
 
 
5. Figure 5: Percent changes from baseline in LDL-C after 150 mg 
PCSK9 monoclonal antibody (SAR236553/REGN727) plus 
atorvastatin 10 or 80 mg/d for 8 weeks in patients with primary 
hypercholesterolemia. Reprinted with permission from Roth et al. 
 
 
 
6. Figure 6: Percent reduction from baseline in LDL-C in the 
Evolocumab group as compared with the placebo group at weeks 12 
and 52.  Reprinted with permission from Blom et al. 
 
 
7. Figure 7: Mean percent changes in LDL cholesterol, total cholesterol, 
and Apo B levels from baseline to week 26 (end of efficacy phase) in 
phase 3 homozygous FH trial. Data available at each time point is 
expressed as mean (SD). Reprinted with permission from Cuchel & 
Meagher et al. 
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